insitro

*Please note, this is a temporary position with the potential to convert to a permanent position.

The Opportunity

Machine learning integrated with biology at scale lies at the core of insitro’s approach to rethinking drug discovery and development. In this role, you will contribute to the core biology platform that insitro is building by working as a key member of the Process Engineering team. You will be working on many aspects of iPSC technology such as iPSC automation, cell line maintenance, and differentiation. This role will primarily focus on supporting the day-to-day activities for the set up, operations, and teardown of our automated cell line management systems.  You will also work with cross-functional teams to identify and develop continuous improvement solutions to improve the reliability and quality of our workflows.  You will possess strong interpersonal skills, a strong collaborative work ethic, ability to adapt to changing needs, and the capacity to multitask to meet key goals. Strong communication and adaptability are essential to success in this position. Occasional weekend work will be required.

About You 

• B.S/M.S. in Biology or equivalent experience and a minimum of 2 years of relevant experience in the pharmaceutical/biotech industry 

• Experience with supporting the operations on laboratory automated platforms
• Meticulous about experimental details and lab work 
• Strong data entry skills 
• Strong team/collaborative skills 
• Strong written and verbal communication skills 
• A desire to transform drug discovery and help patients 

Nice to Have

• An understanding of stem cell-biology, as applied to drug discovery
• Familiarity with creating or editing liquid handling methods 
• Familiarity with standard molecular biology techniques
• Familiarity with reviewing, interpreting technical information, and writing SOPs 

About insitro

insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures.

The company has announced collaborations with Gilead Sciences in the area of NASH (2019) and Bristol Myers Squibb in the area of ALS (2020) and, in mid 2020, completed a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com